FDA approves Adamas' Gocovri for PD dyskinesia

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) gained $5.37 (38%) to $19.60 in after-hours trading Thursday after it said FDA approved Gocovri amantadine (formerly ADS-5102) to treat dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. Adamas said Gocovri is the first FDA-approved drug for the indication.

The company said Gocovri will be made available to patients and physicians next quarter, with a formal launch planned for January 2018. Adamas expects the list price of the drug to be between $10,000 and $30,000...